AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer

AstraZeneca and Daiichi Sankyo have secured US FDA accelerated approval for Datroway (datopotamab deruxtecan) for adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer, marking the first TROP2-directed therapy for lung cancer in the US. This approval, based on a 45% objective response rate in trials, triggers a $45 million milestone payment from AstraZeneca to Daiichi Sankyo, with Daiichi Sankyo recognizing US sales. The drug introduces a novel and needed treatment option for a challenging patient population with limited alternatives, though continued approval is contingent on confirmatory trial data.

Analysis

AstraZeneca (AZN) and Daiichi Sankyo (DSKYF.PK) have secured a significant regulatory milestone with the U.S. FDA's accelerated approval for Datroway for previously treated, advanced EGFR-mutated non-small cell lung cancer (NSCLC). This approval establishes a first-mover advantage, as Datroway is the first TROP2-directed antibody drug conjugate (ADC) therapy for any lung cancer in the US, addressing a patient population with limited later-line treatment options. The decision was based on a compelling 45% objective response rate (ORR) observed in the TROPION-Lung05 Phase II trial. Financially, the approval triggers a $45 million milestone payment from AstraZeneca to Daiichi Sankyo, with Daiichi Sankyo set to recognize all US sales for this indication, making the immediate top-line impact more direct for DSKYF.PK. However, a key risk for investors is the nature of the accelerated approval, which is contingent upon successful verification of clinical benefit in a confirmatory trial. The ongoing evaluation of Datroway in combination with AstraZeneca's blockbuster Tagrisso in Phase III trials (TROPION-Lung14 and TROPION-Lung15) points to a broader strategic effort to expand the drug's label into earlier treatment settings, representing significant future upside potential.

Key Decisions for Investors

• Investors should view this approval as a positive catalyst for both companies, but note that the direct revenue impact from US sales will be booked by Daiichi Sankyo, while AstraZeneca's benefit is tied to the broader collaboration economics and a $45 million milestone payment.
• The primary risk to monitor is the contingent nature of the accelerated approval; investors must closely track the progress and results of the required confirmatory trials, as failure would jeopardize this new revenue stream.
• Significant upside potential lies in the ongoing Phase III trials combining Datroway with Tagrisso, and data readouts from these studies should be watched as key inflection points for expanding the drug's addressable market.
• Given Datroway is the first TROP2-directed therapy for lung cancer, its market adoption and safety profile in a real-world setting should be monitored to assess its competitive positioning and long-term commercial viability.